Can Salivary Innate Immune Molecules Provide Clue on Taste Dysfunction in COVID-19?

Emerging concerns following the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) pandemic are the long-term effects of coronavirus disease (COVID)-19. Dysgeusia in COVID-19 is supported by the abundant expression of the entry receptor, angiotensin-converting enzyme-2 (ACE2), in the oral mucosa. The invading virus perturbs the commensal biofilm and regulates the host responses that permit or suppress viral infection. We correlated the microbial recognition receptors and soluble ACE2 (sACE2) with the SARS-CoV2 measures in the saliva of COVID-19 patients. Data indicate that the toll-like receptor-4, peptidoglycan recognition protein, and sACE2 are elevated in COVID-19 saliva and correlate moderately with the viral load.

[1]  G. Brat,et al.  Evolving Phenotypes of non-hospitalized Patients that Indicate Long Covid , 2021, medRxiv.

[2]  C. Feldman,et al.  The role of co-infections and secondary infections in patients with COVID-19 , 2021, Pneumonia.

[3]  V. Apostolopoulos,et al.  Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells? , 2021, International journal of molecular sciences.

[4]  Shuangge Ma,et al.  Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality , 2021, medRxiv.

[5]  S. Kent,et al.  Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences , 2020, European Respiratory Journal.

[6]  A. Palamara,et al.  Profiling of Oral Microbiota and Cytokines in COVID-19 Patients , 2020, bioRxiv.

[7]  L. de Noronha,et al.  IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection , 2020, Virus Research.

[8]  Eun-Kyeong Jo,et al.  COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis , 2020, bioRxiv.

[9]  M. Srinivasan,et al.  Oral epithelial expression of angiotensin converting enzyme-2: Implications for COVID-19 diagnosis and prognosis , 2020, bioRxiv.

[10]  S. Crovella,et al.  TMPRSS2 and ACE2 Coexpression in SARS-CoV-2 Salivary Glands Infection , 2020, Journal of dental research.

[11]  W. Schaffner,et al.  Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) , 2020, medRxiv.

[12]  S. Mukherjee,et al.  In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs , 2020, Journal of medical virology.

[13]  Martin Stahl,et al.  Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 , 2020, Cell.

[14]  Wen-Tao Ma,et al.  The Commensal Microbiota and Viral Infection: A Comprehensive Review , 2019, Front. Immunol..

[15]  Y. Seta,et al.  ADAM17 regulates TNF-α expression upon lipopolysaccharide stimulation in oral keratinocytes. , 2017, Biomedical research.

[16]  V. Puri,et al.  Role of salivary epithelial toll-like receptors 2 and 4 in modulating innate immune responses in chronic periodontitis. , 2013, Journal of periodontal research.

[17]  O. Jahn,et al.  TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein , 2013, Journal of Virology.

[18]  Jessica C. Wilks,et al.  Dual role of commensal bacteria in viral infections , 2013, Immunological reviews.

[19]  D. Chia,et al.  Direct saliva transcriptome analysis. , 2011, Clinical chemistry.

[20]  T. Ball,et al.  Toll-Like Receptors Dysregulation after Influenza Virus Infection: Insights into Pathogenesis of Subsequent Bacterial Pneumonia , 2011 .

[21]  Hong Wang,et al.  Inflammation Activates the Interferon Signaling Pathways in Taste Bud Cells , 2007, The Journal of Neuroscience.

[22]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.